09:47 AM EST - Small Pharma Inc. : Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment of Major Depressive Disorder met the primary endpoint in its Phase IIa clinical trial, demonstrating a statistically significant and clinically relevant reduction in depressive symptoms at two-weeks post-dose, as compared to placebo. Further analysis of key secondary endpoints demonstrated a rapid and durable antidepressant effect to 12-weeks. Small Pharma Inc.
shares V.DMT are trading unchanged at $0.10.
